Status:

COMPLETED

Sudden Deafness Treatment Trial

Lead Sponsor:

Massachusetts Eye and Ear Infirmary

Collaborating Sponsors:

National Institute on Deafness and Other Communication Disorders (NIDCD)

Conditions:

Sudden Deafness

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hea...

Detailed Description

Sudden deafness is believed to affect 1:5000 people yearly. The cause is unknown. Spontaneous improvement is seen in approximately 20% of subjects. Improvement is seen in approximately 60% of subjects...

Eligibility Criteria

Inclusion

  • Men/women 18 years and older in good health
  • Unilateral sensorineural hearing loss developing within 72 hours (SSNHL)
  • Pure Tone Average (PTA) (500, 1000, 2000, 4000 Hz) \>/= 50 dB in the affected ear, with the affected ear \>/= 30 dB worse than contralateral ear in at least one of the four frequencies
  • Symmetric hearing prior to onset of SSNHL
  • Hearing loss must be idiopathic
  • Hearing loss must have occurred within the past 14 days
  • Must be able to read or write English or Spanish

Exclusion

  • SYSTEMIC DISEASE
  • \>21 days prior oral steroid treatment within preceding 30 days
  • History of tuberculosis (TB) or positive PPD
  • Insulin-dependent diabetes mellitus
  • History of rheumatic disease, e.g., rheumatoid arthritis, scleroderma, lupus, etc.
  • Serious psychiatric disease or psychiatric reaction to corticosteroids
  • History of heart disease or transient ischemic attacks (TIAs)
  • Prior treatment with chemotherapeutic or immunosuppressive drugs
  • Pancreatitis
  • Active peptic ulcer disease or history of gastrointestinal bleeding
  • History of HIV, Hepatitis B or C
  • Chronic kidney failure
  • Alcohol abuse
  • Active shingles
  • Severe osteoporosis or non-surgical aseptic necrosis of the hip
  • OTOLOGIC DISEASE
  • Prior history of SSNHL
  • History of fluctuating hearing loss
  • History of Meniere's disease
  • History of chronic ear infection
  • History of otosclerosis
  • History of ear surgery (except childhood pressure equalization \[pe\] tubes)
  • History of congenital hearing loss
  • History of trauma immediately preceding onset of SSNHL
  • History of syphilitic hearing loss
  • History of genetic/hereditary hearing loss
  • Skull, facial, or temporal bone anomalies

Key Trial Info

Start Date :

December 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2011

Estimated Enrollment :

255 Patients enrolled

Trial Details

Trial ID

NCT00097448

Start Date

December 1 2004

End Date

March 1 2011

Last Update

April 4 2017

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

House Ear Institute

Los Angeles, California, United States, 90057

2

University of California San Diego

San Diego, California, United States, 92103-8895

3

University of Florida, College of Medicine

Gainesville, Florida, United States, 32610

4

University of Iowa

Iowa City, Iowa, United States, 52242-1078

Sudden Deafness Treatment Trial | DecenTrialz